AUTHORS
Dasom (Caroline) Lee, MD, Meelad Amouzgar, PhD2, Arvin Eslami, MD3, Jane Z. Feng4, Nick Phillips5, Alexandria Jensen, Phd6, Kendall Kozy7, Sunny Salazar-White, MD8, Masooma Shifa Rana, MBBS9, Jayasindhu Mallampet10, Francisco Cortina, BS11, Moksha Desai, MS12, Gaurav Dhapola, MS13, Ying-Wen Huang, BS14, Skyler Rietberg, MS15, Xiaoman Kang16, Feng Tian, PhD17, Lena Osswald, MD18, Chih Long Liu, PhD19, Colleen Schweitzer, PhD20, Faisal Cheema, MD21, Sally Arai, MD22, Hany Elmariah, MD,MS23, Laura Johnston, MD24, Vanessa E Kennedy, MD25, Robert Lowsky, MD26, Lekha Mikkilineni, MD, MA27, Lori Muffly, MD28, Robert Negrin, MD29, Andrew Rezvani, MD30, Judith Anne Shizuru, MD, PhD31, Surbhi Sidana, MD32, Wen-Kai Weng, MD, PhD33, Bita Sahaf, PhD34, Yasodha Natkunam, MD, PhD35, Rhine Shen, PhD36, Maximilian Diehn, MD, PhD37, Sushma Bharadwaj, MD38, Melody Smith, MD,MS39, Mathew J. Frank, MD, PhD40, Crystal Mackall, MD41, Zinaida Good, PhD42, Ash A. Alizadeh, MD, PhD43, David Miklos, MD, PhD44, Saurabh Dahiya, MD, FACP45
AFFILIATIONS
1 Stanford University, Stanford, United States
2 Stanford University, Stanford, United States
3 Stanford University, Stanford, United States
4 Stanford University, Stanford, United States
5 Stanford University, Stanford, United States
6 Stanford University, Stanford, United States
7 Stanford University, Stanford, United States
8 Stanford University, Stanford, United States
9 University of Nebraska Medical Center, Omaha, United States
10 Stanford University, Stanford, United States
11 Stanford University, Stanford, United States
12 Stanford University, Stanford, United States
13 Stanford University, Stanford, United States
14 Stanford University, Stanford, United States
15 Stanford University, Stanford, United States
16 Stanford University, Stanford, United States
17 Stanford University, Stanford, United States
18 Stanford University, Stanford, United States
19 Stanford University, Stanford, United States
20 Kite, a Gilead Company, Santa Monica, United States
21 Kaiser Permanente, Santa Clara, United States
22 Stanford University, Stanford, United States
23 Stanford University, Stanford, United States
24 Stanford University, Stanford, United States
25 Stanford University, Stanford, United States
26 Stanford University, Stanford, United States
27 Stanford University, Stanford, United States
28 Stanford University, Stanford, United States
29 Stanford University, Stanford, United States
30 Stanford University, Stanford, United States
31 Stanford University, Stanford, United States
32 Stanford University, Stanford, United States
33 Stanford University, Stanford, United States
34 Stanford University, Stanford, United States
35 Stanford University, Stanford, United States
36 Kite, a Gilead Company, Santa Monica, United States
37 Stanford University, Stanford, United States
38 Stanford University, Stanford, United States
39 Stanford University, Stanford, United States
40 Stanford University, Stanford, United States
41 Stanford University, Stanford, United States
42 Stanford University, Stanford, United States
43 Stanford University, Stanford, United States
44 Stanford University, Stanford, United States
45 Stanford University, Stanford, United States
ABSTRACT
Background
Axi-Cel-2, a second infusion of axicabtagene ciloluecel (Axi-Cel), administered shortly after standard-of-care (SOC) Axi-Cel, aims to overcome high tumor burden, low effector-to-target ratio, and CAR T-cell (CAR-T) exhaustion and improve outcomes in relapsed or refractory large B-cell lymphoma (rrLBCL). Here, we report results from the fully enrolled Phase 1b study evaluating Axi-Cel-2 (ENCORE-1; NCT05794958).
Methods
Adults with rrLBCL, elevated LDH, and second-line (2L) Axi-Cel indication were enrolled. Bridging therapy (BT) was limited to steroids and/or radiation only. After single lymphodepletion, patients (pts) received SOC Axi-Cel followed by Axi-Cel-2 at d7–14 at 0.5×10⁶ CAR+ cells/kg (safety run-in) or 2×10⁶ CAR+ cells/kg (phase 1b). The primary and secondary endpoints were incidence of dose-limiting toxicity (DLT) and 12-month (mo) progression-free survival (PFS), respectively, with target enrollment of 20 pts receiving Axi-Cel-2. Results are referenced to SOC Axi-Cel infusion (d0), and per protocol analysis was conducted.
Serial blood samples were collected over 28 days post SOC Axi-Cel to assess CAR-T kinetics and phenotype using flow cytometry-based method as well as gene expression and clonal dynamics on d7 and d14-17 in fold change using single-cell multi-omics (Good, Nat Med, 2022). Minimal residual disease (MRD) was assessed by PhasED-seq (Kurtz, Nat Biotechnol, 2021) and CD19 antigen loss by H-score (Spiegel, Nat Med, 2021) and EPIC-seq (Esfahani, Nat Biotech, 2022).
Results
As of July 21, 2026, 26 pts were enrolled; 20 received Axi-Cel-2 (3 in safety run-in and 17 in phase 1b). The median age was 65y (45-77y). Seventy-five percent of pts had refractory disease, and 85% had an IPI score ≥3. Median baseline LDH/ULN ratio was 1.33 (1.02-2.32), and 85% received BT. Six pts were ineligible for Axi-Cel-2 due to Gr≥3 ICANS (n=4) or active infection (n=2). The median day of Axi-Cel-2 infusion was 10 (8-14).
No DLTs were observed within 28 days of Axi-Cel-2. Among 4 pts who experienced Gr≥3 ICANS following SOC Axi-Cel, none developed cytokine release syndrome (CRS) or immune effector-associated neurotoxicity (ICANS) after Axi-Cel-2 infusion. Following Axi-Cel-2, 4 pts (20%) developed Gr1 CRS and 1 (5%) developed Gr1 ICANS which resolved within 2 days; no Gr≥2 CRS or ICANS occurred.
At a median follow-up of 14.0 mos (IQR:9.0-19.3), the best overall response rate (95% CI) was 95.0% (75.1-99.9), including best complete response rate of 80.0% (56.3-94.3). The 6-mo rates were 82.5% (66.3-100) for duration of response, 68.9% (51.0-93.2) for PFS, and 95.0% (85.9-100) for overall survival.
A second CAR-T expansion following initial contraction occurred in 88% (15/17) of pts receiving the phase 1b dose. Median CAR-T count at d14 was 6.7 cells/µL (IQR:1.0-19.4) in the Axi-Cel-2 cohort and 1.1 cells/µL (IQR:0.4-5.8) in the 2L SOC historical cohort (P=0.027). Paired intra-patient spectral flow cytometry analysis (n=20) showed reduced expression of the exhaustion markers (PD-1 and CD39) at d14-17 after Axi-Cel-2 compared to d7 after SOC Axi-Cel (Padj<0.01). Paired intra-patient DESeq2 analysis of single-cell RNA-seq (n=19) showed increased stemness (CCR7, LEF1, IL7R) and effector (EOMES, TBX21) transcripts in circulating CAR-Ts at d14-17 after Axi-Cel-2 compared to d7 after SOC Axi-Cel (Padj<0.01). DESeq2 comparison of CAR-Ts at d14-17 in the Axi-Cel-2 cohort (n=19) to those receiving SOC Axi-Cel only (n=6) highlighted an increased stemness program (CCR7, LEF1, TCF7) (Padj<0.01).
MRD analysis of ctDNA was evaluable in 14 pts in Axi-Cel-2 cohort (10 responders and 4 progressors). Median pretreatment ctDNA was 284 hGE/mL (35–6597). Among 10 responders, MRD negativity was 40% at 1 mo and 86% at 3 mos. Among 4 progressors, all were MRD+ at 1 mo, and 3 of 4 had paired biopsies with evaluable H-score showing CD19 antigen downregulation at relapse. Consistently, non-invasive CD19 expression inference using fragmentomic features by EPIC-seq was reduced in blood samples at or before relapse (P=0.04).
Conclusion
ENCORE-1 results demonstrated that Axi-Cel-2 was well tolerated, with no DLTs in the fully enrolled cohort (n=20). Axi-Cel-2 showed promising efficacy, supported by a second CAR-T expansion with less exhausted phenotype, elevated stemness, and deep molecular responses. These findings support the potential of this double-dose strategy to improve outcomes in high-risk rrLBCL. Updated results will be presented at the meeting.
DISCLOSURES
Dasom (Caroline) Lee, MD: Kite, a Gilead Company - Honoraria